Treatment costs of directly observed therapy and traditional therapy for Mycobacterium tuberculosis: A comparative analysis

Stephen Weis, B. Foresman, K. J. Matty, A. Brown, F. X. Blais, G. Burgess, B. King, P. E. Cook, P. C. Slocum

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

OBJECTIVE: Treatment of tuberculosis is a time-consuming and expensive process, often complicated by patient non-adherence. Directly observed therapy (DOT), an out-patient management strategy designed to ensure adherence, is not widely used because it is perceived to be too expensive. This study compared costs of tuberculosis treatment in DOT to the same factors in traditional therapy. DESIGN: A retrospective economic evaluation of 659 tuberculosis cases was reported to a major metropolitan county public health department between 1980 and 1994. Out-patient costs, in-patient costs and the cost impact of relapse and acquired resistance were estimated in 1995 dollars. RESULTS: Treatment costs were lower with DOT: $15 670 per case for in-patient care and $700 per case for out-patient care (P < 0.001). These cost differences resulted from shorter therapy duration (334 vs 550 days), fewer patient hospitalizations (58 vs 75%) and shorter hospital stays (26 vs 55 days per hospitalized patient). Relapse or acquired resistance occurred in 10.9% of patients and accounted for 35.7% of cost with traditional therapy, as compared to 1.2% of patients and 6.0% of cost with observed therapy. CONCLUSIONS: Directly observed therapy is less costly than traditional therapy.

Original languageEnglish
Pages (from-to)976-984
Number of pages9
JournalInternational Journal of Tuberculosis and Lung Disease
Volume3
Issue number11
StatePublished - 1 Nov 1999

Fingerprint

Directly Observed Therapy
Mycobacterium tuberculosis
Health Care Costs
Costs and Cost Analysis
Tuberculosis
Outpatients
Therapeutics
Recurrence
Patient Compliance
Cost-Benefit Analysis
Length of Stay
Patient Care
Hospitalization
Public Health

Keywords

  • Cost
  • DOT
  • Relapse
  • Resistance
  • Tuberculosis

Cite this

Weis, Stephen ; Foresman, B. ; Matty, K. J. ; Brown, A. ; Blais, F. X. ; Burgess, G. ; King, B. ; Cook, P. E. ; Slocum, P. C. / Treatment costs of directly observed therapy and traditional therapy for Mycobacterium tuberculosis : A comparative analysis. In: International Journal of Tuberculosis and Lung Disease. 1999 ; Vol. 3, No. 11. pp. 976-984.
@article{6adcdf62780547108b08d75d09ec4d60,
title = "Treatment costs of directly observed therapy and traditional therapy for Mycobacterium tuberculosis: A comparative analysis",
abstract = "OBJECTIVE: Treatment of tuberculosis is a time-consuming and expensive process, often complicated by patient non-adherence. Directly observed therapy (DOT), an out-patient management strategy designed to ensure adherence, is not widely used because it is perceived to be too expensive. This study compared costs of tuberculosis treatment in DOT to the same factors in traditional therapy. DESIGN: A retrospective economic evaluation of 659 tuberculosis cases was reported to a major metropolitan county public health department between 1980 and 1994. Out-patient costs, in-patient costs and the cost impact of relapse and acquired resistance were estimated in 1995 dollars. RESULTS: Treatment costs were lower with DOT: $15 670 per case for in-patient care and $700 per case for out-patient care (P < 0.001). These cost differences resulted from shorter therapy duration (334 vs 550 days), fewer patient hospitalizations (58 vs 75{\%}) and shorter hospital stays (26 vs 55 days per hospitalized patient). Relapse or acquired resistance occurred in 10.9{\%} of patients and accounted for 35.7{\%} of cost with traditional therapy, as compared to 1.2{\%} of patients and 6.0{\%} of cost with observed therapy. CONCLUSIONS: Directly observed therapy is less costly than traditional therapy.",
keywords = "Cost, DOT, Relapse, Resistance, Tuberculosis",
author = "Stephen Weis and B. Foresman and Matty, {K. J.} and A. Brown and Blais, {F. X.} and G. Burgess and B. King and Cook, {P. E.} and Slocum, {P. C.}",
year = "1999",
month = "11",
day = "1",
language = "English",
volume = "3",
pages = "976--984",
journal = "International Journal of Tuberculosis and Lung Disease",
issn = "1027-3719",
publisher = "International Union Against Tuberculosis and Lung Disease (The Union)",
number = "11",

}

Weis, S, Foresman, B, Matty, KJ, Brown, A, Blais, FX, Burgess, G, King, B, Cook, PE & Slocum, PC 1999, 'Treatment costs of directly observed therapy and traditional therapy for Mycobacterium tuberculosis: A comparative analysis', International Journal of Tuberculosis and Lung Disease, vol. 3, no. 11, pp. 976-984.

Treatment costs of directly observed therapy and traditional therapy for Mycobacterium tuberculosis : A comparative analysis. / Weis, Stephen; Foresman, B.; Matty, K. J.; Brown, A.; Blais, F. X.; Burgess, G.; King, B.; Cook, P. E.; Slocum, P. C.

In: International Journal of Tuberculosis and Lung Disease, Vol. 3, No. 11, 01.11.1999, p. 976-984.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment costs of directly observed therapy and traditional therapy for Mycobacterium tuberculosis

T2 - A comparative analysis

AU - Weis, Stephen

AU - Foresman, B.

AU - Matty, K. J.

AU - Brown, A.

AU - Blais, F. X.

AU - Burgess, G.

AU - King, B.

AU - Cook, P. E.

AU - Slocum, P. C.

PY - 1999/11/1

Y1 - 1999/11/1

N2 - OBJECTIVE: Treatment of tuberculosis is a time-consuming and expensive process, often complicated by patient non-adherence. Directly observed therapy (DOT), an out-patient management strategy designed to ensure adherence, is not widely used because it is perceived to be too expensive. This study compared costs of tuberculosis treatment in DOT to the same factors in traditional therapy. DESIGN: A retrospective economic evaluation of 659 tuberculosis cases was reported to a major metropolitan county public health department between 1980 and 1994. Out-patient costs, in-patient costs and the cost impact of relapse and acquired resistance were estimated in 1995 dollars. RESULTS: Treatment costs were lower with DOT: $15 670 per case for in-patient care and $700 per case for out-patient care (P < 0.001). These cost differences resulted from shorter therapy duration (334 vs 550 days), fewer patient hospitalizations (58 vs 75%) and shorter hospital stays (26 vs 55 days per hospitalized patient). Relapse or acquired resistance occurred in 10.9% of patients and accounted for 35.7% of cost with traditional therapy, as compared to 1.2% of patients and 6.0% of cost with observed therapy. CONCLUSIONS: Directly observed therapy is less costly than traditional therapy.

AB - OBJECTIVE: Treatment of tuberculosis is a time-consuming and expensive process, often complicated by patient non-adherence. Directly observed therapy (DOT), an out-patient management strategy designed to ensure adherence, is not widely used because it is perceived to be too expensive. This study compared costs of tuberculosis treatment in DOT to the same factors in traditional therapy. DESIGN: A retrospective economic evaluation of 659 tuberculosis cases was reported to a major metropolitan county public health department between 1980 and 1994. Out-patient costs, in-patient costs and the cost impact of relapse and acquired resistance were estimated in 1995 dollars. RESULTS: Treatment costs were lower with DOT: $15 670 per case for in-patient care and $700 per case for out-patient care (P < 0.001). These cost differences resulted from shorter therapy duration (334 vs 550 days), fewer patient hospitalizations (58 vs 75%) and shorter hospital stays (26 vs 55 days per hospitalized patient). Relapse or acquired resistance occurred in 10.9% of patients and accounted for 35.7% of cost with traditional therapy, as compared to 1.2% of patients and 6.0% of cost with observed therapy. CONCLUSIONS: Directly observed therapy is less costly than traditional therapy.

KW - Cost

KW - DOT

KW - Relapse

KW - Resistance

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=0032757907&partnerID=8YFLogxK

M3 - Article

C2 - 10587319

AN - SCOPUS:0032757907

VL - 3

SP - 976

EP - 984

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

SN - 1027-3719

IS - 11

ER -